Global Pulmonary/ Respiratory Drug Delivery Market to Reach $59.8 Billion by 2027
Amid the COVID-19 crisis, the global market for Pulmonary/ Respiratory Drug Delivery estimated at US$42.3 Billion in the year 2020, is projected to reach a revised size of US$59.8 Billion by 2027, growing at a CAGR of 5.1% over the analysis period 2020-2027. Metered dose, one of the segments analyzed in the report, is projected to record a 4.9% CAGR and reach US$41.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Dry Powder segment is readjusted to a revised 5.8% CAGR for the next 7-year period.
![Global Market for Pulmonary/ Respiratory Drug Delivery]( "Global Market for Pulmonary/ Respiratory Drug Delivery")
The U.S. Market is Estimated at $12.5 Billion, While China is Forecast to Grow at 4.8% CAGR
The Pulmonary/ Respiratory Drug Delivery market in the U.S. is estimated at US$12.5 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$10.6 Billion by the year 2027 trailing a CAGR of 4.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.9% and 4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.
Nebulizer Segment to Record 5.4% CAGR
In the global Nebulizer segment, USA, Canada, Japan, China and Europe will drive the 5.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.6 Billion in the year 2020 will reach a projected size of US$2.4 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$6.9 Billion by the year 2027.
Select Competitors (Total 42 Featured):
Amid the COVID-19 crisis, the global market for Pulmonary/ Respiratory Drug Delivery estimated at US$42.3 Billion in the year 2020, is projected to reach a revised size of US$59.8 Billion by 2027, growing at a CAGR of 5.1% over the analysis period 2020-2027. Metered dose, one of the segments analyzed in the report, is projected to record a 4.9% CAGR and reach US$41.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Dry Powder segment is readjusted to a revised 5.8% CAGR for the next 7-year period.
The U.S. Market is Estimated at $12.5 Billion, While China is Forecast to Grow at 4.8% CAGR
The Pulmonary/ Respiratory Drug Delivery market in the U.S. is estimated at US$12.5 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$10.6 Billion by the year 2027 trailing a CAGR of 4.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.9% and 4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.
Nebulizer Segment to Record 5.4% CAGR
In the global Nebulizer segment, USA, Canada, Japan, China and Europe will drive the 5.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.6 Billion in the year 2020 will reach a projected size of US$2.4 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$6.9 Billion by the year 2027.
Select Competitors (Total 42 Featured):
- 3M Company
- AstraZeneca PLC
- Boehringer Ingelheim International GmbH
- Cipla Ltd.
- GlaxoSmithKline PLC
- Merck & Co., Inc.
- Novartis AG
- Omron Corporation
- Sunovion Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
Frequently Asked Questions about the Global Market for Pulmonary/ Respiratory Drug Delivery
What is the estimated value of the Global Market for Pulmonary/ Respiratory Drug Delivery?
The Global Market for Pulmonary/ Respiratory Drug Delivery was estimated to be valued at $42.3 Billion in 2020.
What is the growth rate of the Global Market for Pulmonary/ Respiratory Drug Delivery?
The growth rate of the Global Market for Pulmonary/ Respiratory Drug Delivery is 5.1%, with an estimated value of $59.8 Billion by 2027.
What is the forecasted size of the Global Market for Pulmonary/ Respiratory Drug Delivery?
The Global Market for Pulmonary/ Respiratory Drug Delivery is estimated to be worth $59.8 Billion by 2027.
Note: Product cover images may vary from those shown
I. METHODOLOGYII. EXECUTIVE SUMMARY
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 2: World Historic Review for Pulmonary/ Respiratory Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 3: World 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
- Table 4: World Current & Future Analysis for Metered dose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 5: World Historic Review for Metered dose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 6: World 15-Year Perspective for Metered dose by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
- Table 7: World Current & Future Analysis for Dry Powder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 8: World Historic Review for Dry Powder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 9: World 15-Year Perspective for Dry Powder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
- Table 10: World Current & Future Analysis for Nebulizer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 11: World Historic Review for Nebulizer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 12: World 15-Year Perspective for Nebulizer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
- Table 13: World Current & Future Analysis for Accessories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 14: World Historic Review for Accessories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 15: World 15-Year Perspective for Accessories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
- Table 16: World Current & Future Analysis for Chronic Obstructive Pulmonary Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 17: World Historic Review for Chronic Obstructive Pulmonary Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 18: World 15-Year Perspective for Chronic Obstructive Pulmonary Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
- Table 19: World Current & Future Analysis for Asthma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 20: World Historic Review for Asthma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 21: World 15-Year Perspective for Asthma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
- Table 22: World Current & Future Analysis for Cystic Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 23: World Historic Review for Cystic Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 24: World 15-Year Perspective for Cystic Fibrosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
- Table 25: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 26: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 27: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
- UNITED STATES
- Table 28: USA Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 29: USA Historic Review for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 30: USA 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Device Type - Percentage Breakdown of Value Sales for Metered dose, Dry Powder, Nebulizer and Accessories for the Years 2012, 2020 & 2027
- Table 31: USA Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 32: USA Historic Review for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 33: USA 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications for the Years 2012, 2020 & 2027
- CANADA
- Table 34: Canada Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 35: Canada Historic Review for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 36: Canada 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Device Type - Percentage Breakdown of Value Sales for Metered dose, Dry Powder, Nebulizer and Accessories for the Years 2012, 2020 & 2027
- Table 37: Canada Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 38: Canada Historic Review for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 39: Canada 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications for the Years 2012, 2020 & 2027
- JAPAN
- Table 40: Japan Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 41: Japan Historic Review for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 42: Japan 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Device Type - Percentage Breakdown of Value Sales for Metered dose, Dry Powder, Nebulizer and Accessories for the Years 2012, 2020 & 2027
- Table 43: Japan Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 44: Japan Historic Review for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 45: Japan 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications for the Years 2012, 2020 & 2027
- CHINA
- Table 46: China Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 47: China Historic Review for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 48: China 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Device Type - Percentage Breakdown of Value Sales for Metered dose, Dry Powder, Nebulizer and Accessories for the Years 2012, 2020 & 2027
- Table 49: China Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 50: China Historic Review for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 51: China 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications for the Years 2012, 2020 & 2027
- EUROPE
- Table 52: Europe Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 53: Europe Historic Review for Pulmonary/ Respiratory Drug Delivery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 54: Europe 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
- Table 55: Europe Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 56: Europe Historic Review for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 57: Europe 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Device Type - Percentage Breakdown of Value Sales for Metered dose, Dry Powder, Nebulizer and Accessories for the Years 2012, 2020 & 2027
- Table 58: Europe Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 59: Europe Historic Review for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 60: Europe 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications for the Years 2012, 2020 & 2027
- FRANCE
- Table 61: France Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 62: France Historic Review for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 63: France 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Device Type - Percentage Breakdown of Value Sales for Metered dose, Dry Powder, Nebulizer and Accessories for the Years 2012, 2020 & 2027
- Table 64: France Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 65: France Historic Review for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 66: France 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications for the Years 2012, 2020 & 2027
- GERMANY
- Table 67: Germany Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 68: Germany Historic Review for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 69: Germany 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Device Type - Percentage Breakdown of Value Sales for Metered dose, Dry Powder, Nebulizer and Accessories for the Years 2012, 2020 & 2027
- Table 70: Germany Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 71: Germany Historic Review for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 72: Germany 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications for the Years 2012, 2020 & 2027
- ITALY
- Table 73: Italy Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 74: Italy Historic Review for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 75: Italy 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Device Type - Percentage Breakdown of Value Sales for Metered dose, Dry Powder, Nebulizer and Accessories for the Years 2012, 2020 & 2027
- Table 76: Italy Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 77: Italy Historic Review for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 78: Italy 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications for the Years 2012, 2020 & 2027
- UNITED KINGDOM
- Table 79: UK Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 80: UK Historic Review for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 81: UK 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Device Type - Percentage Breakdown of Value Sales for Metered dose, Dry Powder, Nebulizer and Accessories for the Years 2012, 2020 & 2027
- Table 82: UK Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 83: UK Historic Review for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 84: UK 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications for the Years 2012, 2020 & 2027
- REST OF EUROPE
- Table 85: Rest of Europe Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 86: Rest of Europe Historic Review for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 87: Rest of Europe 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Device Type - Percentage Breakdown of Value Sales for Metered dose, Dry Powder, Nebulizer and Accessories for the Years 2012, 2020 & 2027
- Table 88: Rest of Europe Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 89: Rest of Europe Historic Review for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 90: Rest of Europe 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications for the Years 2012, 2020 & 2027
- ASIA-PACIFIC
- Table 91: Asia-Pacific Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 92: Asia-Pacific Historic Review for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 93: Asia-Pacific 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Device Type - Percentage Breakdown of Value Sales for Metered dose, Dry Powder, Nebulizer and Accessories for the Years 2012, 2020 & 2027
- Table 94: Asia-Pacific Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 95: Asia-Pacific Historic Review for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 96: Asia-Pacific 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications for the Years 2012, 2020 & 2027
- REST OF WORLD
- Table 97: Rest of World Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 98: Rest of World Historic Review for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 99: Rest of World 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Device Type - Percentage Breakdown of Value Sales for Metered dose, Dry Powder, Nebulizer and Accessories for the Years 2012, 2020 & 2027
- Table 100: Rest of World Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 101: Rest of World Historic Review for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 102: Rest of World 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications for the Years 2012, 2020 & 2027
IV. COMPETITION
- Total Companies Profiled: 42
Note: Product cover images may vary from those shown
